We’re facing a bit of an anticlimax this week, now that J.P. Morgan has come and gone. But many happenings await us in the wide world of biopharmaceuticals.
New data on Tourette drug
This week, we’re likely going to see Phase 2 data from Neurocrine Biosciences’ study of Ingrezza, a drug that treats Tourette syndrome. Ingrezza, a dopamine-modulating drug, is also being studied in tardive dyskinesia.